The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases.
 
Rana R. McKay
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Batool Haider
Research Funding - Bayer (Inst); Biogen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Novartis (Inst)
 
Mei Sheng Duh
Honoraria - ARIAD
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Expert Testimony - Abbvie
 
Adriana Valdarrama
Employment - Bayer
Stock and Other Ownership Interests - Bayer
Travel, Accommodations, Expenses - Bayer
 
Mari Nakabayashi
No Relationships to Disclose
 
Matthew Fiorillo
No Relationships to Disclose
 
Ljubica Ristovska
Research Funding - Bayer (Inst); Lilly (Inst); Novartis (Inst); Organogenesis (Inst)
 
Lonnie Kent Wen
Employment - Bayer
Stock and Other Ownership Interests - Bayer
Travel, Accommodations, Expenses - Bayer
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi